Life Sciences
Studies from Oregon Health & Science University further understanding of life sciences
Published in Medical Letter on the CDC and FDA, June 15th, 2008
According to recent research from the United States, "Clinicians and patients desiring amenorrhea for therapeutic or social reasons will find continuous-use 90 mu g levonorgestrel/20 mu g ethinyl estradiol to be an attractive oral contraceptive dosing option. Although other formulations of oral contraceptives can be dosed in a continuous manner off -label, the convenience of a 28-day dose pack represents a major advance that will likely increase acceptability of the strategy."
"The availability of FDA-approved continuous-use 90 mu g levonorgestrel/20 mu g ethinyl estradiol will help mainstream continuous oral contraception in the same way that Preven (TM) and Plan B (R)...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Adverse Drug Reactions
Research reports on adverse drug reactions from University of Iowa provide new insights - Arteriovenous Malformation
Study findings from C. Murugesan et al provide new insights into arteriovenous malformation - AVANIR Pharmaceuticals
AVANIR Announces Positive Outcome of Zenvia PK Study - Chronic Pain
Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration - Clinical Trial Research
Orphan Therapeutics Announces Initiation of Rolling NDA Submission for LUCASSIN(R) (terlipressin) for the Treatment of Hepatorenal Syndrome Type 1 - Food and Drug Law Institute
FDLI Publishes Comprehensive Handbook on Pharmaceutical Risk Management - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
